Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

[1]  F. Martinez,et al.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.

[2]  Yoon K Loke,et al.  Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. , 2009, Archives of internal medicine.

[3]  S. Bollmeier,et al.  Long-Acting Bronchodilator Therapy for the Treatment of Chronic Obstructive Pulmonary Disease , 2008, The Annals of pharmacotherapy.

[4]  P. Barnes.  Emerging pharmacotherapies for COPD. , 2008, Chest.

[5]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[6]  D. Spina,et al.  PDE4 inhibitors: current status , 2008, British journal of pharmacology.

[7]  P. Calverley.  COPD: what is the unmet need? , 2008, British journal of pharmacology.

[8]  M. Tunks,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2008 update--highlights for primary care. , 2008, Canadian respiratory journal.

[9]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[10]  L. Fabbri,et al.  Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[11]  K. Rabe,et al.  Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD , 2007, Thorax.

[12]  D. Sin,et al.  Systemic inflammation and mortality in chronic obstructive pulmonary disease. , 2007, Canadian journal of physiology and pharmacology.

[13]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[14]  Sean Keenan,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. , 2007, Canadian respiratory journal.

[15]  M. Cazzola,et al.  Are phosphodiesterase 4 inhibitors just more theophylline? , 2006, The Journal of allergy and clinical immunology.

[16]  E. Bateman,et al.  Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial , 2005, The Lancet.

[17]  B. Lipworth.  Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease , 2005, The Lancet.

[18]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[19]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[20]  Rakesh K. Kumar,et al.  Inhibition of Inflammation and Remodeling by Roflumilast and Dexamethasone in Murine Chronic Asthma , 2003, Journal of Pharmacology and Experimental Therapeutics.

[21]  K. Rabe,et al.  Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease? , 2003, Pulmonary pharmacology & therapeutics.

[22]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[23]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[24]  J. Mancini,et al.  Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors. , 2002, Biochemical pharmacology.

[25]  R. Zuwallack,et al.  Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.

[26]  J. Barsig,et al.  In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. , 2001, The Journal of pharmacology and experimental therapeutics.

[27]  A. Hatzelmann,et al.  Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. , 2001, The Journal of pharmacology and experimental therapeutics.

[28]  R. Kaplan,et al.  Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. , 1998, Chest.

[29]  H. Magnussen,et al.  Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. , 1995, The European respiratory journal.

[30]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[31]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[32]  C. Wells,et al.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.